Armata Secures $2.5 Million DoD Funding for Bacteremia Drug AP-SA02; Phase 3 Set for H2 2026

Armata Pharmaceuticals announced June 23, 2026, it received a $2.5 million award from the U.S. Department of Defense (DoD) to advance its AP-SA02 program, an investigational phage therapeutic targeting Staphylococcus aureus bacteremia. The funding supports preclinical activities for the drug. The award, granted through the DoD's Medical Technology Enterprise Consortium, aims to combat the rising threat of antimicrobial resistance. Armata Pharmaceuticals plans to initiate a Phase 3 clinical trial for AP-SA02 in the second half of 2026, marking a significant step in its development pipeline.